The Schutt Paradigm of Free Amino Ion Alignment & Molecular Stability, and resultant healing technologies, have been in the process of development for more than 30 years and have culminated into the final engineering of hydrogen bonded healing molecules and family of animal and human OTC and ethical pharmaceutical products.
Schutt
The goal of this research has been to develop a technology platform, resulting in disease specific products that would incorporate the theory of cell stabilization into healthy animal care solutions. Success with ethical animal testing provided the opportunity to test theories and formulations in a variety of applications. At the request of attending physicians, who had heard of the successful trials with farm animals, the cell stabilization formulas were also used to provide relief and comfort to critically ill cancer patients.
According to the Schutt Paradigm, when a cell becomes unstable and is unable to restore its stability by process of biosynthesis, the opportunity to mutate can occur. These mutations can lead to a wide variety of problems, some minor, many severe. Over the last three decades, Steven R. Schutt has studied this process. He has invented and developed unique amino acid molecules that release free amino ions which can be integrated into a family of products.
These free amino ions combine with the nucleic acids (within unstable protein nuclei) to achieve the most stable form, and by a process of biosynthesis, causes those formerly unstable proteins to realign. The resulting cellular redifferentiation causes the formerly dysfunctional cells to return to their original preprogrammed function because of already implanted DNA coding. This phenomenon has many positive physiological effects on dysfunctional human and animal cells such as reversing the funcelosa within those dysfunctional cells, thus restoring them to their normal function.
This happens because the cells are differentiated by their original DNA coding, which is still implanted in the errant cells. This process, initiated and achieved by the application of free amino ion releasing products, is thought to be the catalyst in slowing the exponential growth of some cancers as tumorous cells stabilize and are able to return to their normal functioning.
LD 50 studies with 50% H2O solutions and CP powder forms of Triamino™ have shown that the molecule is non-toxic. Pure powder oral ingestion, vapor inhalation, intra-arterial and intravenous administration of Triamino™ in high concentrations all failed to achieve a lethal dose or any visible side effects on mice or rats.
The ramifications of this discovery are enormous. This new molecule will be the cornerstone for a family of health, beauty, and medical products and services.
The Triamino™ molecular structure is fully biocompatible, non-allergenic and does not elicit immune reaction, local or systemic toxicity, or inflammation in animals.
Validation
Our Founder and Director of Scientific Development, Mr. Steven Schutt, acknowledged the discovery announced on January 16, 2011 by the Imperial College of London which substantiates his own research and analysis of protein behavior as outlined in his publication, “Free Amino Ion Theory.” [Full Imperial College of London Findings Here]
Udalova
Dr. Irina Udalova, Senior Researcher at the Imperial College of London’s Kennedy Institute of Rheumatology, has identified a protein that acts as a “master switch” in certain white blood cells, determining whether the cells promote or inhibit inflammation of the protein identified as IRF5. Cells of the immune system called macrophages can either stimulate inflammation or suppress it by releasing chemical signals that alter the behavior of other cells. Inflammatory responses are an important defense the body uses against harmful stimuli such as infections or tissue damage.
Mr. Schutt believed that this study, published in the journal Nature Immunology, provides additional, verifiable evidence that unstable proteins can cause dysfunctional cells. The result of Dr. Udalova’s study augments Mr. Schutt’s own careful research combining free amino acids with the nucleic acids to cause formerly unstable proteins to realign. This study provides further convincing evidence of the efficacy of both of Mr. Schutt’s formulae, Triamino™ and TAFA400™.
More than thirty seven years in development, the Triamino™ Formula is a unique and revolutionary Amino Ion releasing hydrogen-bonded molecule. Triamino™ has been tested for verification by means of a series of sophisticated trials utilizing NMR (Nuclear Magnetic Resonance). In addition, an internationally recognized bio-research laboratory has conducted a series of LD 50 studies consisting of inoculations by subcutaneous infusion, intravenous injection, inhalation and oral feeding. All test results indicate this new molecule is essentially non-toxic with no side effects, and is considered as safe as distilled water. This new molecule is a water-soluble blend of amino acids that embodies nature- based healing agents delivered through oral, inhalant, topical, and both inter-and intra- (arterial or venous) administration. The structure of this new Triamino™ molecule is based on a proprietary formula that facilitates healing across a broad spectrum of medical ailments and health conditions. It does so because the Free Amino Ions in Hydrous solution inundate and bond to the nucleic acids within the unstable proteins of dysfunctional cells. The resultant biosynthesis causes the unstable proteins to align and become stable, returning the cells to their normal functioning as programmed by their original DNA coding which is still implanted within their DNA structure. This mechanism also causes reactivation of the Proliferative phase regulated by the DNA, thus significantly accelerating the healing process. The Triamino™ molecule is derived from natural, based amino-acids which ensure an FDA GRAS (Generally Recognized As Safe) status. The molecule is not a pharmaceutical drug. It has multiple applications in the treatment of both human and animal health issues.
Triamino Fulvate (TAFA400™) is the second and newest Molecule developed by Mr. Schutt and is available in a unique formula that combines the Triamino™ Molecule & Fulvic Acid (Carbohydrate Derived Fulvic Acid) that eliminates the problems encountered with mineral derived Fulvic Acid. Internationally CHD Fulvic Acid in a chemically pure pharmaceutical grade has not only augmented the Triamino™ molecule, but has added to the benefits of Triamino™ to produce the most effective non-toxic, all-natural broad spectrum anti- fungal, anti-bacterial, anti-microbial, anti-viral agent known to mankind. This new formulation gives it the propensity to more easily bond to the nucleic acids within the cellular protein and causes the nucleus to function as originally programmed by its DNA. The addition of Fulvic Acid to the Triamino™ Molecule aids in the bonding process because fulvates strongly bond to all proteins.
Toxic microbes, viruses and fungi do not and cannot form immunity to the action of the fulvate component of this motity due to its superb ability to bond to the protein portion of the covering membrane of microbial cells, viral forms and fungi. Triamino Fulvate (TAFA400™) can be regarded as a non-specific entry inhibitor to viral coat proteins. It exhibits broad spectrum anti-viral activity against most envelope viruses such as Vaccinia, Herpes, HIV, Hepatitis C, and Influenza, including H5Nl. This new molecule notably maintains all the benefits of Triamino™ and adds the superb anti-microbial, anti-viral and anti-fungal effects of CHD Fulvic Acid without any toxic side effects. It also accelerates the speed of Triamino™’s anti-inflammatory action.